ATE203745T1 - Neue n-(arylsulfonyl)aminosäurederivate mit einer affinität für bradykininrezeptoren - Google Patents

Neue n-(arylsulfonyl)aminosäurederivate mit einer affinität für bradykininrezeptoren

Info

Publication number
ATE203745T1
ATE203745T1 AT97900243T AT97900243T ATE203745T1 AT E203745 T1 ATE203745 T1 AT E203745T1 AT 97900243 T AT97900243 T AT 97900243T AT 97900243 T AT97900243 T AT 97900243T AT E203745 T1 ATE203745 T1 AT E203745T1
Authority
AT
Austria
Prior art keywords
arylsulfonyl
affinity
new
amino acid
acid derivatives
Prior art date
Application number
AT97900243T
Other languages
English (en)
Inventor
Bernard Ferrari
Jean Gougat
Claude Muneaux
Yvette Muneaux
Pierre Perreaut
Claudine Planchenault
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9488041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE203745(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE203745T1 publication Critical patent/ATE203745T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97900243T 1996-01-11 1997-01-07 Neue n-(arylsulfonyl)aminosäurederivate mit einer affinität für bradykininrezeptoren ATE203745T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9600269A FR2743562B1 (fr) 1996-01-11 1996-01-11 Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
PCT/FR1997/000026 WO1997025315A1 (fr) 1996-01-11 1997-01-07 Nouveaux derives de n-(arylsulfonyl)aminoacides ayant une affinite pour les recepteurs de la bradykinine

Publications (1)

Publication Number Publication Date
ATE203745T1 true ATE203745T1 (de) 2001-08-15

Family

ID=9488041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97900243T ATE203745T1 (de) 1996-01-11 1997-01-07 Neue n-(arylsulfonyl)aminosäurederivate mit einer affinität für bradykininrezeptoren

Country Status (12)

Country Link
US (3) US6015812A (de)
EP (1) EP0877737B1 (de)
JP (1) JP4086316B2 (de)
AT (1) ATE203745T1 (de)
AU (1) AU1383297A (de)
BR (1) BR9707120B1 (de)
DE (1) DE69705930T2 (de)
ES (1) ES2162231T3 (de)
FR (1) FR2743562B1 (de)
MX (1) MX9805289A (de)
NO (1) NO310975B1 (de)
WO (1) WO1997025315A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
DE69716449T2 (de) 1996-08-28 2003-08-07 The Procter & Gamble Company, Cincinnati Substituierte zyklische amine als metalloproteaseinhibitoren
GB9621814D0 (en) * 1996-10-19 1996-12-11 British Biotech Pharm Metalloproteinase inhibitors
FR2765222B1 (fr) * 1997-06-27 1999-12-31 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
KR100352316B1 (ko) 1997-07-31 2002-09-12 더 프록터 앤드 갬블 캄파니 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
PL350340A1 (en) 1999-03-03 2002-12-02 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
HK1044935A1 (zh) 1999-03-03 2002-11-08 The Procter & Gamble Company 双异取代的金属蛋白酶抑制剂
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
FR2819254B1 (fr) * 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
FR2822827B1 (fr) 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2002092556A1 (en) * 2001-05-14 2002-11-21 Novartis Ag Sulfonamide derivatives
US6919343B2 (en) * 2002-02-08 2005-07-19 Merck & Co., Inc. N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
AU2003217728B2 (en) * 2002-02-08 2008-11-20 Merck Sharp & Dohme Corp. N-Biphenylmethyl aminocycloalkanecarboxamide derivatives
AU2003217764A1 (en) 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
FR2840897B1 (fr) 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
EP1562925B1 (de) * 2002-11-07 2007-01-03 Merck & Co., Inc. Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
FR2852958B1 (fr) * 2003-03-25 2005-06-24 Fournier Lab Sa Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique
WO2004087700A1 (fr) * 2003-03-25 2004-10-14 Laboratoires Fournier S.A. Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
US7211566B2 (en) * 2003-04-01 2007-05-01 Universite De Sherbrooke Selective bradykinin (BK) B1 peptidic receptor antagonists and uses thereof
AU2004231070B2 (en) 2003-04-10 2008-02-14 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
CA2522084A1 (en) 2003-04-10 2004-10-28 Amgen Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
US7414134B2 (en) * 2004-10-12 2008-08-19 Amgen Inc. B1 bradykinin receptor antagonists
WO2006044355A1 (en) 2004-10-13 2006-04-27 Amgen Inc. Triazoles and their use as bradykinin b1 receptor antagonists
ATE518849T1 (de) * 2008-02-06 2011-08-15 Boehringer Ingelheim Int Arylsulfonamide wirksam als schmerzmittel
MX2010011095A (es) * 2008-04-08 2010-11-05 Gruenenthal Gmbh Derivados de sulfonamidas sustituidos.
CA2752190A1 (en) 2009-02-13 2010-08-19 Jerini Ag Small molecule bradykinin b1 receptor antagonists
WO2011000863A1 (en) * 2009-07-01 2011-01-06 Dsm Ip Assets B.V. Sulfonamide derivatives for use in the treatment of skin conditions
EP2316820A1 (de) 2009-10-28 2011-05-04 Dompe S.p.A. Als Bradykinin-Rezeptorantagonisten nützliche 2-Arylpropionamid-Derivate und pharmazeutische Zusammensetzungen damit
SMT201700161T1 (it) 2013-06-14 2017-05-08 Dompe Farm Spa Antagonisti del recettore della bradichinina e composizioni farmaceutiche che li contengono
EP3740482A1 (de) 2018-01-17 2020-11-25 Migal Galilee Research Institute Ltd. Neue inhibitoren des methionin-stoffwechselweges
CN111630032B (zh) * 2018-01-17 2024-06-07 米加尔-加利里研究院有限公司 新型蛋氨酸代谢途径抑制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
AU1383297A (en) 1997-08-01
ES2162231T3 (es) 2001-12-16
FR2743562A1 (fr) 1997-07-18
JP4086316B2 (ja) 2008-05-14
FR2743562B1 (fr) 1998-04-03
JP2000504315A (ja) 2000-04-11
NO983190L (no) 1998-07-10
US6100278A (en) 2000-08-08
DE69705930D1 (de) 2001-09-06
US6313120B1 (en) 2001-11-06
DE69705930T2 (de) 2002-04-11
MX9805289A (es) 1998-10-31
US6015812A (en) 2000-01-18
BR9707120A (pt) 1999-07-20
EP0877737A1 (de) 1998-11-18
EP0877737B1 (de) 2001-08-01
WO1997025315A1 (fr) 1997-07-17
BR9707120B1 (pt) 2010-10-05
NO310975B1 (no) 2001-09-24

Similar Documents

Publication Publication Date Title
ATE203745T1 (de) Neue n-(arylsulfonyl)aminosäurederivate mit einer affinität für bradykininrezeptoren
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
ATE213727T1 (de) In position 3 durch eine stickstoffgruppe substituierte 1,3-dihydroindol-2-on derivate als vasopressin und/oder ocytocin agonisten und/oder antagonisten
DE69621831D1 (de) Piperazinderivative als tachykinin antagonisten
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
BG101110A (bg) Заместени пиримидинови съединения и тяхното използване
ATE286038T1 (de) Verbindungen mit sulfonsäure-amidgruppe
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
DE60103050D1 (de) Spiro[2.4]heptanaminocarbonsäure und ihre derivate
MXPA02001340A (es) Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
ATE230392T1 (de) Amidinophenyl-pyrrolidine, -pyrroline und - isoxazolidine und ihre derivate
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
TR200002542T2 (tr) Meta-azasiklik amino benzoik asit bileşikleri ve bunların integrin antagonistleri olan türevleri
SE9703414D0 (sv) New compounds
ES2138983T3 (es) Uso de derivados del acido 2-(n-(2-aminoetil)amino)-acetico para el tratamiento de enfermedades condicionadas por glicosilacion no enzimatica.
ATE275545T1 (de) Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
ATE199013T1 (de) N-(4-substituerte benzyl)-2-aminolactamderivate
TR200101979T2 (tr) Antidepresyon tedavisi için 5HT1 antagonistleri.
DE59510713D1 (de) N-substituierte 3-azabicyclo(3.2.0)heptan-derivate als neuroleptika
ATE165101T1 (de) Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
ATE441642T1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
DE69939586D1 (de) Inhibitoren für die gefässneubildung
MX9603199A (es) Antagonistas de receptores a endotelina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties